Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by HighteawithIntrepidon Sep 11, 2017 11:33am
194 Views
Post# 26679800

RE:RE:For conscripts only

RE:RE:For conscripts onlyFred thanks. What the believers sometimes forget is that I started calling the TST crew conscripts 
to give us a common moniker vs the .07 believers, but pretty much anyone that  has an ACB above 2.50 could consider themselves a conscript. This is from the email:
September 7, 2017 – NovaVive Inc., an animal health immunobiology company, is pleased to announce that it has signed a co-operation agreement with Hoken Biotechnology (Beijing) Co., Ltd. Under the agreement, Hoken has become the exclusive distributor for NovaVive’s cattle immunotherapeutic, Amplimune™, in The People’s Republic of China, the Kingdom of Thailand, Malaysia and the Republic of Indonesia.
Amplimune is a potent immunomodulator that reduces the clinical signs and mortality associated with E. coli K99 diarrhea in neonatal calves. The product is an emulsion of mycobacterium cell wall fractions (MCWF) that enhances innate immunity to fight bacterial infections without the use of antibiotics. The product has regulatory approval currently in Canada and the U.S.
 
Veterinarians and cattle producers are under increasing pressure to reduce antibiotic therapies used in animals, particularly food producing animals like cattle. E. colidiarrhea in calves is typically treated with antibiotics. 
 
HT
Bullboard Posts